- Immucor, Inc. (NASDAQ: BLUD) is a leading supplier of diagnostic reagents and automated instrumentation to ensure the safety of blood transfusions
- Immucor has established direct distribution in many global markets, but its Japanese distribution rights were exclusively held by Kainos Laboratories, Inc., a publicly traded Japanese company
- Immucor retained TM Capital to structure and negotiate the acquisition of the blood bank distribution division of Kainos and achieve direct distribution in Japan
- TM Capital assisted Immucor in the formation of a joint venture with Kainos providing Immucor with immediate 51% ownership of its Japanese distribution company and eventual 100% ownership
For more information, contact our healthcare team at:
“I have relied on TM Capital for a range of strategic and financial advice for several years. Their impact as our advisor is best evidenced by the fact that our market capitalization has grown from $75 million to over $1 billion over this period.””Edward L. Gallup, Chairman & CEO, Immucor, Inc.